+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 85Years
All Genders
ID04215809

Phase 1 Study of APG-2575 Lisaftoclax Alone or With Rituximab or Acalabrutinib in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Led by Ascentage Pharma Group Inc. · Updated on 2025-04-10

144

Participants Needed

9

Research Sites

86 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating lisaftoclax, a drug being studied alone or combined with other therapies, for patients with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The main goals are to assess the safety, tolerability, identify dose-limiting toxicities DLT, and determine the maximum tolerated dose MTD or recommended phase 2 dose RP2D of lisaftoclax. This research focuses on patients who need treatment after prior therapies and aims to better understand the dosing and safety profile of this drug. The trial is conducted in two parts, each including a ramp-up period, dose escalation, and dose expansion phases. The ramp-up involves gradually increasing doses of lisaftoclax from 20 mg to up to 1,000 mg daily over several days, depending on the assigned dose level. Part 1 studies lisaftoclax alone at various doses 400 mg, 600 mg, 800 mg, and 1,000 mg, while Part 2 evaluates lisaftoclax combined with rituximab or acalabrutinib through a dose escalation and expansion design to further assess safety and anticancer activity. Participants will be closely monitored with assessments including safety evaluations and toxicity checks over a 42-day period to identify dose-limiting toxicities and maximum tolerated dose. The study requires patients to attend visits for treatment administration, follow-up examinations, and to provide informed consent. Researchers will track outcomes related to safety and dosing to inform future studies. The trial is designed for adults aged 18 to 85 with relapsed or refractory CLLSLL, and participants will be followed throughout the study duration as per protocol.

CONDITIONS

Brief Title

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Research Team

L

Laura Glass

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here